Detalles de la búsqueda
1.
BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis.
Clin Exp Rheumatol
; 39(2): 365-371, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-32662409
2.
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(12): 1351-60, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25273343
3.
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
Lancet Oncol
; 15(11): 1269-78, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25273342
4.
Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study.
Rheumatol Adv Pract
; 7(2): rkad031, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37122809
5.
PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis.
Therap Adv Gastroenterol
; 16: 17562848221145654, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36936799
6.
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Pharmacoeconomics
; 40(3): 323-339, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34921350
7.
Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study.
Mult Scler Relat Disord
; 46: 102543, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33296966
8.
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review.
Rheumatol Ther
; 6(3): 317-338, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31385263
9.
Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
J Neurol
; 265(12): 2980-2992, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30327931
10.
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
Lung Cancer
; 99: 94-101, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27565921
11.
ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis.
J Neurol Sci
; 351(1-2): 174-178, 2015 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25758472
12.
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet Neurol
; 13(4): 353-63, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24613349
13.
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
J Clin Oncol
; 32(13): 1309-16, 2014 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24687829
14.
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Eur J Cancer
; 49(18): 3831-8, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24007819
15.
Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer).
Eur J Cancer
; 50(4): 862-3, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24418723
Resultados
1 -
15
de 15
1
Próxima >
>>